Table 2.
Parameters used for the evaluation of the effects on patients’ outcome
| Clinical examination | ||
| Strength level of upper and lower extremities at last physical examination using Medical Research Council classification (scale: 0–5) | ||
| Sonographic examination | ||
| Diaphragm | M. quadriceps femoris | |
| Personal data | ||
| Age (years) | Sex (m/f/d) | Height (cm) |
| Weight (kg) | Diagnosis | Chronic conditions |
| Laboratory values from clinical routine in last 24h | ||
| Medication | ||
| Sufentanil (μg/d) | Insulin bolus + infusion (IU) | |
| Piritramide (mg/d) | Naloxone (mg/d) | |
| Midazolam (mg) | Sodium picosulfate (mg/d) | |
| Dexmedetomidin (μg/d) | Neostigmine (mg/d) | |
| Propofol (mg/d) | Macrogol 3350 (units/d) | |
| Clinical data | ||
| SOFA score | Operative status | |
| APACHE II score | Min. Horovitz index (mmHg) | |
| SAPS II score | max. PEEP (mbar) | |
| RASS score | max. Pinsp (mbar) | |
| VAS score | max. respiratory rate (x/min) | |
| GCS score | Data organ replacement (yes/no) | |
| Temperature (°C) | ECMO therapy (yes/no) | |
| Mean arterial pressure (mmHg) | Duration of invasive ventilation since admission (hours) | |
| Heart rate (bpm) | Duration of non-invasive ventilation since admission (hours) | |
| Cardiac index (L/min) | Duration of invasive ventilation since admission (0.0–1000.0) | |
| Bicarbonate (mmol/L) | Export urine (mL) | |
| Blood pH | AKIN stadium | |
| Lactate (mmol/L) | ||
| Amount of reflux (mL) | ||
| Bowel movement (active/sluggish /none) | ||
| Amount of stool (frequent/average/little) | ||